UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Sana Biotechnology, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 83-1381173 | |
(State or incorporation or organization) | (IRS Employer Identification No.) |
188 East Blaine Street, Suite 400 Seattle, Washington |
98102 | |
(Address of Principal Executive Offices) | (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class to be so registered |
Name of each exchange on which
each class is to be registered
|
|
Common stock, par value $0.0001 per share | The Nasdaq Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-252061.
Securities to be registered pursuant to Section 12(g) of the Act: None.
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. Description of Registrants Securities to be Registered.
Sana Biotechnology, Inc. (the Company) hereby incorporates by reference herein the description of its common stock, par value $0.0001 per share (the Common Stock), to be registered hereunder, set forth under the heading Description of Capital Stock in the Companys prospectus constituting part of the Registration Statement on Form S-1 (File No. 333-252061) of the Company, initially filed on January 13, 2021 with the Securities and Exchange Commission (the Commission) under the Securities Act of 1933, as amended (the Securities Act). The description of the Common Stock included in any form of prospectus subsequently filed by the Company with the Commission shall be deemed to be incorporated by reference herein. The Common Stock is expected to be listed on The Nasdaq Stock Market LLC.
Item 2. Exhibits.
Pursuant to the instructions as to exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Company are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
Date: January 25, 2021 | Sana Biotechnology, Inc. | |||||
By: |
/s/ Steven D. Harr, M.D. |
|||||
Name: | Steven D. Harr, M.D. | |||||
Title: | President and Chief Executive Officer |